Reviewing Seaport Therapeutics (SPTX) and Its Competitors

Seaport Therapeutics (NASDAQ:SPTX) is one of 907 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Seaport Therapeutics to related businesses based on the strength of its earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Seaport Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2	3	5	0	2.30
Seaport Therapeutics Competitors	7634	13739	25648	1003	2.42

Seaport Therapeutics presently has a consensus price target of $38.40, suggesting a potential upside of 61.55%. As a group, “Pharmaceuticals” companies have a potential upside of 31.37%. Given Seaport Therapeutics’ higher probable upside, equities research analysts plainly believe Seaport Therapeutics is more favorable than its rivals.

Profitability

This table compares Seaport Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Seaport Therapeutics Competitors	-2,324.62%	-215.62%	-16.81%

Earnings & Valuation

This table compares Seaport Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seaport Therapeutics	N/A	-$74.88 million	-2.30
Seaport Therapeutics Competitors	$3.53 billion	$3.12 billion	536.76

Seaport Therapeutics’ rivals have higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.0% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Seaport Therapeutics rivals beat Seaport Therapeutics on 8 of the 12 factors compared.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.